Neurotoxicity Monitoring During Disease-Modifying Neurological Therapies

Abstract

Neurotoxicity is a significant concern in patients undergoing disease-modifying neurological therapies (DMNTs), given the expanding array of pharmacological agents now available for neurological disorders. This review synthesizes current evidence on the epidemiology, pathophysiology, risk factors, clinical features, diagnostic strategies, management, and recent advances in neurotoxicity monitoring. Emphasis is placed on guideline-driven practices and practical clinical insights to optimize patient safety and outcomes during DMNTs.

Introduction

Disease-modifying neurological therapies have revolutionized the care of conditions such as multiple sclerosis (MS), epilepsy, neuromuscular diseases, and neuroinflammatory disorders. With increasing utilization of immunomodulators, monoclonal antibodies, and targeted small molecules, vigilance for adverse neurological effects including neurotoxicity has become paramount. Proactive neurotoxicity monitoring ensures early detection, mitigation of irreversible harm, and safe long-term disease management. Recent advancements in therapeutic modalities and monitoring technologies have further underscored the need for rigorous, evidence-based approaches in clinical practice.

Epidemiology / Disease Burden

The incidence of neurotoxicity associated with DMNTs varies by drug class, patient population, and underlying neurological disease. For example, natalizumab-induced progressive multifocal leukoencephalopathy (PML) has an estimated risk ranging from 0.1% to 4% depending on treatment duration and serostatus. In contrast, chemotherapy-induced neurotoxicity in neuro-oncology patients may affect up to 60% of individuals, manifesting as peripheral neuropathy, cognitive dysfunction, or seizures. The burden is compounded by under-recognition and the potential for cumulative, irreversible neurological deficits, emphasizing the need for systematic surveillance protocols in at-risk populations.

Pathophysiology

Neurotoxicity during DMNTs arises via diverse mechanisms, including direct neuronal injury, disruption of blood-brain barrier integrity, immune-mediated demyelination, mitochondrial dysfunction, and excitotoxicity. Monoclonal antibodies targeting immune checkpoints or integrins may trigger unintended neuroinflammation or reactivation of latent infections (e.g., JC virus). Small molecule inhibitors, such as fingolimod, can alter sphingolipid metabolism, affecting neuronal signaling and myelin integrity. Chemotherapeutic agents often induce oxidative stress or impair microtubule function, leading to axonal degeneration. Understanding these mechanisms informs both risk stratification and development of neuroprotective adjuncts.

Risk Factors

Identifying patients at heightened risk for neurotoxicity is critical for targeted monitoring. Risk factors include advanced age, pre-existing neurological impairment, concomitant nephrotoxic or neurotoxic medications, genetic polymorphisms affecting drug metabolism (e.g., CYP450 variants), cumulative drug dose, and immunosuppression status. For example, JC virus seropositivity and prior immunosuppressant use increase PML risk in natalizumab-treated patients. Pharmacogenomic markers are increasingly recognized as valuable tools for individualized risk assessment, allowing for tailored therapeutic strategies and monitoring regimens.

Clinical Features

Clinical manifestations of neurotoxicity are variable and may be subtle or rapidly progressive. Symptoms can include cognitive impairment, peripheral neuropathy, ataxia, seizures, encephalopathy, visual disturbances, or psychiatric changes. The temporal profile may differ by agent; for instance, acute neurotoxicity can occur with high-dose corticosteroids, while delayed cognitive decline is more typical of certain chemotherapeutics. Early recognition of atypical symptomatology is essential, as prompt intervention can prevent irreversible damage. Regular neurological assessments employing standardized scales (e.g., Expanded Disability Status Scale, Montreal Cognitive Assessment) are recommended.

Diagnosis

Diagnosis of neurotoxicity relies on a combination of clinical evaluation, neuroimaging, electrophysiological studies, laboratory testing, and exclusion of alternative etiologies. Magnetic resonance imaging (MRI) with advanced sequences (e.g., diffusion tensor imaging, FLAIR) is invaluable for detecting demyelination, edema, or microstructural changes. Cerebrospinal fluid analysis may reveal inflammatory markers or infectious agents (e.g., JC virus PCR). Nerve conduction studies and electromyography assist in distinguishing peripheral from central neurotoxicity. Periodic neuropsychological testing is recommended for therapies associated with cognitive risk. A multidisciplinary approach, involving neurology, pharmacy, and infectious disease specialists, enhances diagnostic accuracy.

Treatment & Management

Management of neurotoxicity entails prompt cessation or dose adjustment of the offending agent, symptomatic therapy, and, where appropriate, initiation of neuroprotective or immunomodulatory interventions. Specific antidotes exist for some agents (e.g., high-dose corticosteroids for immune-mediated neurotoxicity); however, supportive care remains the mainstay for most cases. Rehabilitation services, including physical, occupational, and speech therapy, play a vital role in functional recovery. Close monitoring for recurrence or progression is essential, especially in patients requiring ongoing DMNTs. Interdisciplinary coordination and patient education are crucial to optimize outcomes and minimize treatment interruptions.

Recent Advances / Emerging Therapies

Recent years have witnessed significant progress in neurotoxicity monitoring, including the integration of digital health platforms, wearable sensors, and biomarker discovery. Serum neurofilament light chain (NfL) has emerged as a promising biomarker for axonal injury, correlating with both subclinical and overt neurotoxicity across several DMNTs. Artificial intelligence-driven analysis of neuroimaging and real-time patient-reported outcomes enable earlier detection of subtle changes. Novel therapeutic agents with improved selectivity and reduced blood-brain barrier penetration are being developed to minimize neurotoxic risk, while ongoing clinical trials explore neuroprotective co-therapies and personalized dosing algorithms.

Guideline Recommendations

Professional guidelines from organizations such as the American Academy of Neurology (AAN), European Federation of Neurological Societies (EFNS), and National Comprehensive Cancer Network (NCCN) advocate for baseline and periodic neurological assessments during DMNTs. Recommendations include pre-treatment risk stratification, routine laboratory and imaging surveillance, patient and caregiver education regarding warning signs, and prompt multidisciplinary intervention in case of suspected neurotoxicity. Integration of validated clinical scales and standardized monitoring protocols is emphasized to facilitate early detection and uniform reporting in both clinical practice and research settings.

Conclusion

Neurotoxicity remains a clinically significant and potentially preventable complication of disease-modifying neurological therapies. A comprehensive, mechanism-based approach to monitoring incorporating risk assessment, vigilant clinical evaluation, advanced diagnostics, and adherence to evidence-based guidelines can substantially mitigate harm and optimize therapeutic outcomes. Continued innovation in biomarkers, digital tools, and precision medicine will further enhance clinician's ability to safeguard neurological health during DMNTs, ultimately improving quality of care for individuals with complex neurological diseases.